"What" Series

What is the latest time to start a clinical drug trial after approval?

19 April 2024
2 min read

After a drug clinical trial is approved, it must commence within three years from the date of approval. If no subject has signed an informed consent form within these three years, the approval for the drug clinical trial becomes automatically invalid. If there is still a need to conduct the drug clinical trial, a new application must be submitted.

If the approval for a drug clinical trial has expired and the applicant wishes to continue the clinical trial, they must re-submit a drug clinical trial application and obtain approval again following the prescribed procedures.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

48-Week Frexalimab Trial Shows Sustained Multiple Sclerosis Treatment Promise
Latest Hotspot
3 min read
48-Week Frexalimab Trial Shows Sustained Multiple Sclerosis Treatment Promise
19 April 2024
Press Announcement: Latest 48-week stage 2 findings on frexalimab indicate promising consistent effectiveness in treating multiple sclerosis.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 19
Pharma Frontiers
12 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 19
19 April 2024
April 19th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Alvotech, Teva Gain FDA Approval for Stelara® Biosimilar SELARSDI™
Latest Hotspot
4 min read
Alvotech, Teva Gain FDA Approval for Stelara® Biosimilar SELARSDI™
19 April 2024
Alvotech and Teva have received FDA clearance in the U.S. for their product SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab).
Read →
What is the difference between synthetic peptides and recombinant peptides?
"What" Series
2 min read
What is the difference between synthetic peptides and recombinant peptides?
19 April 2024
Comparing Synthetic and Recombinant Peptide Production: Processes, Applications, Costs, and Scalability.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.